You are here:Home-Research Areas-Cancer-Ovarian Cancer

Request The Product List ofOvarian Cancer Ovarian Cancer

Cat. No. Product Name CAS No. Information



Pamiparib (BGB-290, BGB290) is a highly potent, selective and brain penetrant PARP1/2 inhibitor with potent anti-tumor activity.

Ovarian Cancer

Phase 2 Clinical




Cridanimod (10-carboxymethyl-9-acridanone, 10-CMA, XBIO-101) is a potent type I interferon (IFN) inducer that directly binds to STING and triggers a strong antiviral response through the TBK1/IRF3 route; displays extraordinary activity in phosphorylating IRF3 in the murine system; also increases progesterone receptor (PrR) expression in endometrial tissue.

Ovarian Cancer

Phase 2 Clinical




Triapine (3-AP, PAN-811, OCX191, NSC 663249) is a potent ribonucleotide reductase inhibitor with broad spectrum antitumor activity.

Ovarian Cancer

Phase 2 Clinical




Trabectedin (Ecteinascidin-743, ET-743, Ecteinascidin) is a marine alkaloid isolated from the Caribbean tunicate Ecteinascidia turbinata that shows remarkably anticancer activity in a variety of in vitro and in vivo systems; a DNA minor groove, guanine-specific alkylating agent; shows hign potency against ovarian carcinoma xenografts.

Ovarian Cancer





MK-4827 (Niraparib, MK4827) is a highly potent PARP inhibitor with IC50 of 3.8 nM/2.1 nM for PARP1/PARP2; inhibits PARP activity with EC50=4 nM in a whole cell assay, and inhibits proliferation of cancer cells with mutant BRCA-1 and BRCA-2 with CC50 in the 10−100 nM range; well tolerated in vivo and demonstrates efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer.

Ovarian Cancer



DEBIO 1143

1071992-99-8 DEBIO 1143 (AT-406, DEBIO-1143, SM406, ARRY-334543, D1143) is potent, orally active Smac mimetic that antagonizes cIAP1, cIAP2 and XIAP with Ki of 66.4, 1.9 and 5.1 nM, respectively; effectively antagonizes XIAP BIR3 protein in cell-free functional assays, induces rapid degradation of cellular cIAP1 protein, and inhibits cancer cell growth in various human cancer cell lines; effectively induces apoptosis and causes complete inhibition of tumor growth apoptosis in xenograft tumors.

Ovarian Cancer

Phase 2 Clinical



2222344-98-9 ORIC-101 (ORIC101) is a highly potent, selective steroidal glucocorticoid receptor (GR) antagonist (IC50=5.6 nM) with reduced androgen receptor (AR) agonistic activity; dose-dependently reduces the expression levels of two established GR target genes, GILZ and FKBP5 with IC50 of 24.9 and 19.5 nM in human PBMCs; demonstrates in vivo antitumor activity by enhancing response to chemotherapy in the GR+ OVCAR5 ovarian cancer xenograft model.

Ovarian Cancer

Phase 1 Clinical

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us